Ghanim Jasim Mohammed¹, Youssef Shakuri Yasin² and Firas Shawqi Algburi³

College of Medicine-Department of Clinical Biochemistry, Tikrit University, Iraq

*Corresponding Author: Ghanim Jassim Mohammed, College of Medicine-Department of Clinical Biochemistry, Tikrit University, Iraq.

Received: March 28, 2024; Published: April 24, 2024

Abstract

Objective: This study was done to evaluate dialysis's impact on serum renalase and catecholamines (epinephrine, dopamine, and norepinephrine) in Kirkuk City patients with end-stage renal disease.

Method: The study was conducted at the Al-Amal Kidney Dialysis Unit in Kirkuk from December 1, 2023, to March 1, 2024. A total of 180 individuals were allocated into three distinct groups for the study. Initial participants in renal dialysis. The second group underwent a 4-hour dialysis treatment, whereas the third group consisted of healthy individuals without chronic renal disease. Before and after dialysis, Renalase and Catecholamine levels were assessed in all study participants.

Results: study results reveled to, after 4 hours from dialysis, patients with end stage renal disease exhibit improvement in the level of renalase enzyme comparing with renalase level before dialysis, while the level of catecholamines showed lowering in end stage renal disease patients after 4 hours from dialysis comparing with its levels before dialysis.

Conclusion: Dialysis elevated renalase levels, resulting in a reduction of circulating catecholamines such as epinephrine, norepinephrine, and dopamine. Patients suffering from advanced kidney failure and heart disease necessitate dialysis due to the ability of renalase to lower the levels of circulating catecholamines, thereby mitigating cardiovascular damage.

 Keywords: End Stage Renal Disease; Dialysis; Renalase Enzyme; Catecholamines; Kirkuk City

References

1. ADEYOMOYE OI., et al. “The biological roles of urea: A review of preclinical studies”. Indian Journal of Nephrology 32 (2022): 539-545.
2. BLAKELEY S. “Renal failure and replacement therapies, Springer Science and Business Media.
3. CLATWORTHY M. “Nephrology: clinical cases uncovered, John Wiley and Sons (2010).
4. CORSELLO A., et al. “Walter E. Dandy: his contributions to pituitary surgery in the context of the overall Johns Hopkins Hospital Experience”. Pituitary 20 (2017): 683-691.
5. DANZIGER J and HOENIG MPJAJOKD. “The role of the kidney in disorders of volume: core curriculum”. American Journal of Kidney Disease 68 (2016): 808-816.
6. DESIR GV., et al. “Renalase lowers ambulatory blood pressure by metabolizing circulating adrenaline”. Journal of the American Heart Association 1 (2012): e002634.
7. DESIR GVJKI. “Regulation of blood pressure and cardiovascular function by renalase”. Hypertension Research 76 (2009): 366-370.
8. DIABETES MJN. “National Institute of Diabetes and Digestive and Kidney Diseases” (2017).
9. HAUSBERG M., et al. “Sympathetic nerve activity in end-stage renal disease”. Circulation 106 (2002): 1974-1979.
10. JOLES JA and KOOMANS HAJH. “Causes and consequences of increased sympathetic activity in renal disease”. Hypertension 43 (2004): 699-706.
11. JUMAA AH., et al. “Esomeprazole and Amygdalin combination cytotoxic effect on human cervical cancer cell line (Hela cancer cell line)”. Iraqi Journal of Cancer and Medical Genetics 10 (2018): 2236-2241.
12. KERR JF., et al. “Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics”. British Journal of Cancer 26 (1972): 239-257.
13. LANGER P and CHARNEY A. “Renal Case Report (2019).
14. LI G., et al. “Catecholamines regulate the activity, secretion, and synthesis of renalase”. Circulation 117 (2008): 1277-1282.
15. LIAO MT., et al. “Insulin resistance in patients with chronic kidney disease”. BMC Nephrology (2012).
16. MAHDI S., et al. “Effect of different concentrations of Bovine Serum Albumin on some of the frozen sperm characteristics of the rams”. Plant Archives 19 (2019): 1486-1488.
17. MILANI M., et al. “FAD-binding site and NADP reactivity in human renalase: a new enzyme involved in blood pressure regulation”. Journal of Molecular Biology 411 (2011): 463-473.
18. OGUZ EG., et al. “Increased serum renalase in hemodialysis patients: is it related to left ventricular hypertrophy?” Renal Failure 38 (2016): 1180-1186.
19. SALMAN IMJCHR. “Cardiovascular autonomic dysfunction in chronic kidney disease: a comprehensive review”. Current Hypertension Reports 17 (2015): 1-20.
20. SCHNELLMANN RGJC. “DOULL’S TOXICOLOGY THE BASIC SCIENCE OF POISONS, N. Y. T. M.-H. 2001”. Toxic Responses of the Kidney (2001).
21. SEBASTIAN M. “Renal toxicity. Handbook of Toxicology of Chemical Warfare Agents. Elsevier (2009).
22. SERWIN NM., et al. “Serum-to-urine renalase ratio and renalase fractional excretion in healthy adults and chronic kidney disease patients”. BMC Nephrology 21 (2020): 1-7.
23. SEVERINA I., et al. “The history of renalase from amine oxidase to alpha-NAD (P) H-oxidase/anomerase”. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry 61 (2015): 667-679.
24. SKRZYPCZYK P., et al. “Renalase in children with chronic kidney disease”. Biomarkers 24 (2019): 638-644.
25. WANG F., et al. “Epinephrine evokes renalase secretion via a-adrenoceptor/NF-κB pathways in renal proximal tubular epithelial cells”. Kidney and Blood Pressure Research 39 (2014): 252-259.
26. WANG F., et al. “Serum renalase is related to catecholamine levels and renal function”. Clinical and Experimental Nephrology 19 (2015): 92-98.
27. WANG J., et al. “Identification, expression and tissue distribution of a renalase homologue from mouse”. Molecular Biology Reports 35 (2008): 613-620.
28. WEXLER DJ., et al. “Research gaps in gestational diabetes mellitus: executive summary of a national institute of diabetes and digestive and kidney diseases workshop”. Obstetrics and Gynecology 132 (2018): 496-505.
29. WISNIEWSKA M., et al. “Renalase in haemodialysis patients with chronic kidney disease”. Journal of Clinical Medicine 10 (2021): 680.
30. XU J., et al. “Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure”. Journal of Clinical Investigation 115 (2005): 1275-1280.
31. YASIN YS., et al. “Effect of Laetrile Vinblastine Combination on the Proliferation of the Hela Cancer Cell Line”. Asian Pacific Journal of Cancer Prevention 24 (2023): 4329.

Citation

Citation: Ghanim Jassim Mohammed. “Evaluate the Influence of Renalase Enzyme on Catecholamine Levels Before and After Dialysis in Patients with Renal Failure in Kirkuk City”.Acta Scientific Medical Sciences 8.5 (2024): 76-81.

Copyright

Copyright: © 2024 Ghanim Jassim Mohammed. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.